CompletedNot Applicable

Effects of Low-Level Laser Therapy on Oxidative Stress Levels

Turkey (Türkiye)46 participantsStarted 2021-02-09

Plain-language summary

Hashimoto's thyroiditis (HT) is the most commonly observed inflammatory and autoimmune disease of the thyroid gland. Recent evidence has suggested that low-level laser therapy (LLLT) can improve thyroid function and reduce levels of thyroid peroxidase antibodies (TPOAb) in patients with hypothyroidism caused by chronic autoimmune thyroiditis. In the literature, data examining the effects of LLLT on oxidative stress level and quality of life in patients with HT is limited. The aim of the study is to examine the effects of LT4 treatment combined with LLLT on thyroid autoimmunity, oxidative stress and quality of life in patients with Hashimoto's diagnosis.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Cases between the ages of 18-65 who applied to the Kosuyolu Istanbul Medipol Hospital Endocrinology and Metabolic Diseases Clinic between 2020-2021 and diagnosed as "Hashimoto Thyroiditis" by a specialist physician will be included in the study. Exclusion Criteria: * Acute infection * Use of immunosuppressants, immunostimulants and drugs that interfere with the production, transport, and metabolism of thyroid hormones * Thyroid nodules * Tracheal stenosis * Serious illness * History of exposure to ionizing radiation and/or neoplasia in the cervical region * Malignancy and a history of thyroid surgery * Hypothyrodism caused by postpartum thyroiditis * Pregnancy and breastfeeding period * Identification and diagnosis of the cases with neurological and psychiatric disorders.

What they're measuring

Oxidative Stress Levels

Timeframe: 3 months

Malondialdehyde (MDA)

Timeframe: 3 months

Nitric oxide (NO)

Timeframe: 3 months

Superoxide dismutase (SOD)

Timeframe: 3 months

Catalase (CAT)

Timeframe: 3 months

Glutathione (GSH)

Timeframe: 3 months

Trial details

NCT IDNCT04754607

SponsorIstanbul Medipol University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-04-15

View on ClinicalTrials.gov More Hashimoto Thyroiditis trials

Plain-language summary

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.